Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Open accessThe DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Abstract
Owing to their small size and safety profiles, adeno-associated viruses (AAVs) have become the vector of choice for gene therapy applications in the retina. In addition to the naturally occurring AAVs, several engineered variants with enhanced properties are being developed for experimental and therapeutic applications. Nonetheless, there are still some challenges impeding successful application of AAVs for a broader range of retinal gene therapies. The small size of AAV particles ensures efficient tissue transduction but also limits the packaging capacity to a few kilobases. Further, AAV's ability to cross retinal barriers is still an obstacle to pan-retinal transduction of the outer retina with tolerable doses. Lastly, despite overall safety, there have been recent reports of immune responses to AAVs in the eye. Hence, evaluation and prediction of immune responses to AAVs has come to be considered an integral part of future clinical success. This review focuses on the use of AAV in clinical trials for retinal diseases, and discusses developments of variants and novel strategies to overcome immune responses to AAVs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A significant barrier to effective intraocular rAAV gene delivery is the interaction of the vector with the host’s immune system [5].”
From Characterization of anti-AAV2 neutralizing antibody levels in sheep prior to and following intravitreal AAV2.7m8 injection (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wong, W. L., Su, X., Li, X., Cheung, C. M. G., Klein, R., Cheng, C.-Y., & Wong, T. Y. (2014) · The Lancet Global Health · doi:10.1016/s2214-109x(13)70145-1 · Cited by 5,331
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 2×
“BEs are DNA editing tools that use a dead Cas9 (dCas9; no/residual catalytic activity) fused with cytidine (CBEs) or adenine (ABEs) deaminases allowing single base conversion of C:G>T:A or A:T> G:C.(27,58) This strategy is particularly relevant in both monogenic autosomal recessive and autosomal dominant diseases cont…”
BackgroundNon-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123 · cited 1×
“Non-viral vectors are a heterogenous family including various components such as lipid nanoparticles (LNPs), polymer-based vectors, or inorganic materials.(75,76) Nonetheless, when it comes to the retina, those vectors, which are bigger (~100–200nm) than AAVs (~25nm), may face numerous physical and physiological barri…”
BackgroundIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0561-9 · Cited by 2,237
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924 · cited 1×
“However, long-term follow-up in 2 out of 3 clinical trials reported a decline in the visual gains in adult patients, indicating that the treatment was unable to halt the degeneration.(15,19) This highlights two important aspects: the level of AAV transduction required for therapeutic benefits in humans may be higher a…”
BackgroundCRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202 · cited 1×
“The proof-of-concept for vision restoration was provided in a canine model.(14) This led to clinical trials involving LCA2 patients who received SR injections of RPE65 packaged in AAV2 via SR delivery.”
BackgroundBoutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Non Viral Vectors in Gene Therapy- An Overview
Ramamoorth, M. (2015) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2015/10443.5394 · Cited by 761
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“AAV relies on the host cell mechanisms for the second strand synthesis.(7) For experimental and clinical applications recombinant AAVs (rAAV) are created by replacing the viral genome by the transgene of interest while retaining the ITRs.”
MethodDalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734 · cited 3×
“The first AAV variant capable of overcoming the ILM barrier was found through directed evolution and is called AAV2-7m8, a variant that has a sevenamino acid insert at R587.(37) This mutation confers the ability to partially evade HS binding and the “sink” effect of these proteoglycans at the ILM.”
BackgroundInfluentialSelf-citationDevelopment of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
Maeder, M. L., Stefanidakis, M., Wilson, C. J., Baral, R., Barrera, L. A., Bounoutas, G. S., Bumcrot, D., Chao, H., Ciulla, D. M., DaSilva, J. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0327-9 · Cited by 707
Partial recovery of visual function in a blind patient after optogenetic therapy
Sahel, J.-A., Boulanger-Scemama, E., Pagot, C., Arleo, A., Galluppi, F., Martel, J. N., Esposti, S. D., Delaux, A., de Saint Aubert, J.-B., de Montleau, C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01351-4 · Cited by 700
Self-citationGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Engineered Virus-like Particles for Efficient in Vivo Delivery of Therapeutic Proteins
Banskota, S., Raguram, A., Suh, S., Du, S. W., Davis, J. R., Choi, E. H., Wang, X., Nielsen, S. C., Newby, G. A., Randolph, P. B., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.021 · Cited by 668 · cited 1×
“mimicking the form and size of a virus particle, but lacking the viral genetic material and being non-infectious.(139) These new developments are interesting but none of these have efficiencies comparable to AAVs, thereby preventing their usage in vivo for retinal gene therapy applications.”
BackgroundTranscriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019) · Nature · doi:10.1038/s41586-019-1161-z · Cited by 663
Jacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Lipid Nanoparticles for Drug Delivery
Xu, L., Wang, X., Liu, Y., Yang, G., Falconer, R. J., & Zhao, C.-X. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202100109 · Cited by 545
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“The best variants identified in this screen had 10 to 100 fold higher resistance to neutralizing antibodies.(103) Another study used the capsid shuffling method (wherein the capsid sequences of known AAVs are fragmented and reassembled to generate variant sequences) to generate AAV variants library and screen these to…”
BackgroundInfectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532 · cited 1×
“Following internalization AAVs escape the endosomes and gain entry into the nucleus.(6) AAV relies on the host cell mechanisms for the second strand synthesis.”
BackgroundInfluentialThi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
ICTV Virus Taxonomy Profile: Parvoviridae
Cotmore, S. F., Agbandje-McKenna, M., Canuti, M., Chiorini, J. A., Eis-Hubinger, A.-M., Hughes, J., Mietzsch, M., Modha, S., Ogliastro, M., Pénzes, J. J., et al. (2019) · Journal of General Virology · doi:10.1099/jgv.0.001212 · Cited by 523
Levy, J. M., Yeh, W.-H., Pendse, N., Davis, J. R., Hennessey, E., Butcher, R., Koblan, L. W., Comander, J., Liu, Q., & Liu, D. R. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0501-5 · Cited by 477
Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects
Zu, H., & Gao, D. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00608-7 · Cited by 475
Bennett, J., Wellman, J., Marshall, K. A., McCague, S., Ashtari, M., DiStefano-Pappas, J., Elci, O. U., Chung, D. C., Sun, J., Wright, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30371-3 · Cited by 461 · cited 4×
“Formation of the bleb under the fovea has also resulted in retinal thinning.(18) Moreover, AAV has limited reach outside of the bleb due to restricted lateral spread.”
BackgroundInfluentialSamulski, R. J., Chang, L. S., & Shenk, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.10.3096-3101.1987 · Cited by 449
High levels of AAV vector integration into CRISPR-induced DNA breaks
Hanlon, K. S., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Volak, A., Spirig, S. E., Muller, A., Sousa, A. A., Tsai, S. Q., Bengtsson, N. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12449-2 · Cited by 431
Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410
High-efficiency transduction of the mouse retina by tyrosine-mutant AAV serotype vectors
Petrs-Silva, H., Dinculescu, A., Li, Q., Min, S.-H., Chiodo, V., Pang, J.-J., Zhong, L., Zolotukhin, S., Srivastava, A., Lewin, A. S., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2008.269 · Cited by 398
Improvement and Decline in Vision with Gene Therapy in Childhood Blindness
Jacobson, S. G., Cideciyan, A. V., Roman, A. J., Sumaroka, A., Schwartz, S. B., Heon, E., & Hauswirth, W. W. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412965 · Cited by 372
Development of an intein-mediated split-Cas9 system for gene therapy
Truong, D.-J. J., Kühner, K., Kühn, R., Werfel, S., Engelhardt, S., Wurst, W., & Ortiz, O. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv601 · Cited by 371 · cited 1×
“Thus, reconstitution occurs at the protein level.(60,61) Two recent studies showed interesting results in rd12 mice, an LCA model involving the RPE65 gene with nonsense mutation c.”
ResultInner limiting membrane barriers to aav-mediated retinal transduction from the vitreous
Dalkara, D., Kolstad, K. D., Caporale, N., Visel, M., Klimczak, R. R., Schaffer, D. V., & Flannery, J. G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.181 · Cited by 357
Self-citationComprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356 · cited 1×
“Moreover, computational methods have recently helped guide capsid engineering and the understanding of AAV biology.(113) Currently, it is possible to develop AAV variants with high viability using in silico design, and in future, with the study of complex directed evolution datasets, machine learning and AI can aid re…”
MethodDefining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355 · cited 1×
“A higher transduction and low immunogenicity was reported when delivered systemically.(129) Another study used a similar strategy with additional inhibition of macrophages reporting improved transduction.”
ResultNanoparticles in the clinic: An update post COVID‐19 vaccines
Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10246 · Cited by 337
Testa, F., Maguire, A. M., Rossi, S., Pierce, E. A., Melillo, P., Marshall, K., Banfi, S., Surace, E. M., Sun, J., Acerra, C., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.048 · Cited by 330
Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle
Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Chérel, Y., Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00649-08 · Cited by 317
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Deep diversification of an AAV capsid protein by machine learning
Bryant, D. H., Bashir, A., Sinai, S., Jain, N. K., Ogden, P. J., Riley, P. F., Church, G. M., Colwell, L. J., & Kelsic, E. D. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00793-4 · Cited by 300
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Rivera, V. M., Gao, G.-P., Grant, R. L., Schnell, M. A., Zoltick, P. W., Rozamus, L. W., Clackson, T., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-06-2501 · Cited by 276
Effective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina
Petrs-Silva, H., Dinculescu, A., Li, Q., Deng, W.-T., Pang, J.-J., Min, S.-H., Chiodo, V., Neeley, A. W., Govindasamy, L., Bennett, A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.234 · Cited by 267
Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 2×
“They reported inhibition of IFN-γ T-cell responses toward capsid and transgene resulting in minimal cellular infiltrate and stable transgene expression.(135) As mentioned earlier, immune responses occur upon interaction of CpG motifs on viral DNA with TLR receptors on immune cells.”
BackgroundAAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey
Vandenberghe, L. H., Bell, P., Maguire, A. M., Cearley, C. N., Xiao, R., Calcedo, R., Wang, L., Castle, M. J., Maguire, A. C., Grant, R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002103 · Cited by 242
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 1×
“They designed the transgene sequences to include the TLRi sequences and reported lower immune responses and higher transduction efficiency in mouse and pig models.(134) A study evaluated immune responses in Tlr null mutant (Tlr9-/-) and wild-type mice after injections of an immunogenic AAV variant (AAVrh32.”
BackgroundTse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M., & Zarbin, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 208
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Davis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., & Liu, D. R. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00911-4 · Cited by 192
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190 · cited 1×
“The therapeutic gene is packaged into AAVs and delivered to target tissue by local injections.(9) AAV delivery to the retina is normally done by two routes: subretinal and”
BackgroundSelf-citationVector platforms for gene therapy of inherited retinopathies
Trapani, I., Puppo, A., & Auricchio, A. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.08.001 · Cited by 183
Persistent remodeling and neurodegeneration in late-stage retinal degeneration
Pfeiffer, R. L., Marc, R. E., & Jones, B. W. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.07.004 · Cited by 178
PEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 1×
“However, when the ratio of PEG/AAV was increased the transduction efficiency reduced most likely because excessive coverage with PEGs reduced the exposure of the AAV capsid regions essential for infectivity.(124) Some researchers have also attempted encapsulating the AAV capsid within gel beads or polymeric particles…”
BackgroundGenome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degeneration
Kim, K., Park, S. W., Kim, J. H., Lee, S. H., Kim, D., Koo, T., Kim, K.-E., Kim, J. H., & Kim, J.-S. (2017) · Genome Research · doi:10.1101/gr.219089.116 · Cited by 163
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
Gene delivery to the eye using adeno-associated viral vectors
Martin, K. R. G., Klein, R. L., & Quigley, H. A. (2002) · Methods · doi:10.1016/s1046-2023(02)00232-3 · Cited by 149 · cited 1×
“Intravitreal injection (IVT) involves AAV delivery into the vitreous space thereby causing transduction of the Ganglion Cell Layer (GCL) and some other cell types of the inner retina.(10) The retina is an ideal target for gene therapy due to two main reasons: First, many gene mutations responsible for Inherited Retina…”
BackgroundEvaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina
Ramachandran, P. S., Lee, V., Wei, Z., Song, J. Y., Casal, G., Cronin, T., Willett, K., Huckfeldt, R., Morgan, J. I. W., Aleman, T. S., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.111 · Cited by 147
Sehara, Y., Fujimoto, K.-I., Ikeguchi, K., Katakai, Y., Ono, F., Takino, N., Ito, M., Ozawa, K., & Muramatsu, S.-I. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.010 · Cited by 141
Amado, D., Mingozzi, F., Hui, D., Bennicelli, J. L., Wei, Z., Chen, Y., Bote, E., Grant, R. L., Golden, J. A., Narfstrom, K., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000659 · Cited by 140 · cited 1×
“Such readministration has been tested in non-human primates and also reported in clinical trials.(18,118) Furthermore, presently efficient delivery to the photoreceptors is achieved by subretinal injections in clinical settings.”
BackgroundWeindler, F. W., & Heilbronn, R. (1991) · Journal of Virology · doi:10.1128/jvi.65.5.2476-2483.1991 · Cited by 136
Perabo, L., Goldnau, D., White, K., Endell, J., Boucas, J., Humme, S., Work, L. M., Janicki, H., Hallek, M., Baker, A. H., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00076-06 · Cited by 134
Clinical applications of retinal gene therapy
Lipinski, D. M., Thake, M., & MacLaren, R. E. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2012.09.001 · Cited by 132
Dyka, F. M., Boye, S. L., Chiodo, V. A., Hauswirth, W. W., & Boye, S. E. (2014) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.212 · Cited by 128 · cited 1×
“One of the problems with dual/triple AAV strategies is the risk of producing truncated proteins, which have been reported previously.(48,51,55) As it raises safety concerns, these issues must be addressed for future clinical applications.”
BackgroundTriple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Noninvasive gene delivery to foveal cones for vision restoration
Khabou, H., Garita-Hernandez, M., Chaffiol, A., Reichman, S., Jaillard, C., Brazhnikova, E., Bertin, S., Forster, V., Desrosiers, M., Winckler, C., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96029 · Cited by 124
Self-citationEngineering Biomaterial Systems to Enhance Viral Vector Gene Delivery
Jang, J.-H., Schaffer, D. V., & Shea, L. D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.111 · Cited by 123
Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117
Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff, A. M., Börner, K., Albrecht, B., Schäfer, W., Baum, N., Haag, F., Körbelin, J., Trepel, M., Braren, I., Grimm, D., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.003 · Cited by 106
Immunology of AAV-Mediated Gene Transfer in the Eye
Willett, K., & Bennett, J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00261 · Cited by 105 · cited 1×
“The retina is shielded by a blood-retinal barrier and also benefits from the unique intraocular microenvironment.(12) This prevents the occurrence of a strong systemic effect to the AAV-mediated ocular gene therapy.”
BackgroundIn vivo–directed evolution of adeno-associated virus in the primate retina
Byrne, L. C., Day, T. P., Visel, M., Strazzeri, J. A., Fortuny, C., Dalkara, D., Merigan, W. H., Schaffer, D. V., & Flannery, J. G. (2020) · JCI Insight · doi:10.1172/jci.insight.135112 · Cited by 104
Self-citationHuman cytomegalovirus completely helps adeno-associated virus replication
McPherson, R. A., Rosenthal, L. J., & Rose, J. A. (1985) · Virology · doi:10.1016/0042-6822(85)90243-0 · Cited by 101
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit
Petris, G., Casini, A., Montagna, C., Lorenzin, F., Prandi, D., Romanel, A., Zasso, J., Conti, L., Demichelis, F., & Cereseto, A. (2017) · Nature Communications · doi:10.1038/ncomms15334 · Cited by 98
Choi, E. H., Suh, S., Foik, A. T., Leinonen, H., Newby, G. A., Gao, X. D., Banskota, S., Hoang, T., Du, S. W., Dong, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29490-3 · Cited by 96
Trapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94
Dosage thresholds and influence of transgene cassette in adeno-associated virus–related toxicity
Khabou, H., Cordeau, C., Pacot, L., Fisson, S., & Dalkara, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.144 · Cited by 93 · cited 1×
“A comparison CAG (ubiquitous) and Rho (cell-specific) promoters reported reduction in retinal function (measured by ERG) with ubiquitous promoter.(116) Another study compared the effect of many ubiquitous (CAG, CMV, UbiC) and cell-specific (RedO, Rho, CAR, GRK, Best1) promoters.”
BackgroundSelf-citationHigh-purity production and precise editing of DNA base editing ribonucleoproteins
Jang, H.-K., Jo, D. H., Lee, S.-N., Cho, C. S., Jeong, Y. K., Jung, Y., Yu, J., Kim, J. H., Woo, J.-S., & Bae, S. (2021) · Science Advances · doi:10.1126/sciadv.abg2661 · Cited by 93 · cited 1×
“8% and 6% efficiency, respectively, leading to phenotype improvement only with AAV-ABEs suggesting a better clinical relevance.(62,88) These advances are encouraging and their development in parallel with that of AAV approaches is crucial to develop safer therapeutic methods.”
BackgroundBenedicto, I., Lehmann, G. L., Ginsberg, M. D., Nolan, D. J., Bareja, R., Elemento, O., Salfati, Z., Alam, N. M., Prusky, G. T., Llanos, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms15374 · Cited by 92
Peynshaert, K., Devoldere, J., Minnaert, A.-K., De Smedt, S. C., & Remaut, K. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1565890 · Cited by 92
Buck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86 · cited 2×
“Even if the reconstitution efficiency is low, phenotypic improvement in disease models have been reported in previous studies.(52,54,55) Furthermore, some genes involved in genetic disease are still larger than dual-AAVs capacity.”
ResultUtility of PEGylated recombinant adeno-associated viruses for gene transfer
Le, H. T., Yu, Q.-C., Wilson, J. M., & Croyle, M. A. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.019 · Cited by 82
Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa
Meng, D., Ragi, S. D., & Tsang, S. H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.012 · Cited by 82
A Self-restricted CRISPR System to Reduce Off-target Effects
Chen, Y., Liu, X., Zhang, Y., Wang, H., Ying, H., Liu, M., Li, D., Lui, K. O., & Ding, Q. (2016) · Molecular Therapy · doi:10.1038/mt.2016.172 · Cited by 81
Non-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
Boye, S. L., Bennett, A., Scalabrino, M. L., McCullough, K. T., Van Vliet, K., Choudhury, S., Ruan, Q., Peterson, J., Agbandje-McKenna, M., & Boye, S. E. (2016) · Journal of Virology · doi:10.1128/jvi.00200-16 · Cited by 79
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Adenine Base Editing In Vivo with a Single Adeno-Associated Virus Vector
Zhang, H., Bamidele, N., Liu, P., Ojelabi, O., Gao, X. D., Rodríguez, T., Cheng, H., Kelly, K. L., Watts, J. K., Xie, J., et al. (2022) · GEN Biotechnology · doi:10.1089/genbio.2022.0015 · Cited by 69
Yao, T., Zhou, X., Zhang, C., Yu, X., Tian, Z., Zhang, L., & Zhou, D. (2017) · Molecules · doi:10.3390/molecules22071155 · Cited by 68
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
The Effect of CpG Sequences on Capsid-Specific CD8+ T Cell Responses to AAV Vector Gene Transfer
Xiang, Z., Kurupati, R. K., Li, Y., Kuranda, K., Zhou, X., Mingozzi, F., High, K. A., & Ertl, H. C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.014 · Cited by 67
Öztürk, B. E., Johnson, M. E., Kleyman, M., Turunç, S., He, J., Jabalameli, S., Xi, Z., Visel, M., Dufour, V., Iwabe, S., et al. (2021) · eLife · doi:10.7554/elife.64175 · Cited by 66
Optogenetics for visual restoration: From proof of principle to translational challenges
Lindner, M., Gilhooley, M. J., Hughes, S., & Hankins, M. W. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2022.101089 · Cited by 65
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63 · cited 1×
“So far, this vector has been tested in mouse and NHP retinas, and confirms the promising possibilities of capsid development in silico.(101)”
BackgroundSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61 · cited 3×
“Studies in non-human primates reported the highest seroprevalence was against AAV8 and AAV9, while AAV5 was the lowest.(45,46) Irrespective of the pre-existing immunity, AAVs can trigger an immune response in the eye.”
BackgroundSelf-citationJo, D. H., Jang, H.-K., Cho, C. S., Han, J. H., Ryu, G., Jung, Y., Bae, S., & Kim, J. H. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2022.11.021 · Cited by 59
Chien, Y., Hsiao, Y.-J., Chou, S.-J., Lin, T.-Y., Yarmishyn, A. A., Lai, W.-Y., Lee, M.-S., Lin, Y.-Y., Lin, T.-W., Hwang, D.-K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 57
Retinal transduction profiles by high-capacity viral vectors
Puppo, A., Cesi, G., Marrocco, E., Piccolo, P., Jacca, S., Shayakhmetov, D. M., Parks, R. J., Davidson, B. L., Colloca, S., Brunetti-Pierri, N., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.57 · Cited by 56
Precision genome editing in the eye
Suh, S., Choi, E. H., Raguram, A., Liu, D. R., & Palczewski, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210104119 · Cited by 54
Expanding Adeno-associated Viral Vector Capacity: A Tale of Two Vectors
Ghosh, A., & Duan, D. (2007) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2007.10648098 · Cited by 53
Wang, D., Zhong, L., Li, M., Li, J., Tran, K., Ren, L., He, R., Xie, J., Moser, R. P., Fraser, C., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.09.003 · Cited by 53
Rational engineering of a functional CpG-free ITR for AAV gene therapy
Pan, X., Yue, Y., Boftsi, M., Wasala, L. P., Tran, N. T., Zhang, K., Pintel, D. J., Tai, P. W. L., & Duan, D. (2022) · Gene Therapy · doi:10.1038/s41434-021-00296-0 · Cited by 53
Ren, D., Fisson, S., Dalkara, D., & Ail, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091973 · Cited by 52 · cited 1×
“These pre-existing BAbs and NAbs are serotype, species, age and population specific.(44) The highest seroprevalence in the human population was for anti-AAV2 antibodies, while antiAAV8 was the lowest.”
BackgroundSelf-citationGallego, I., Villate-Beitia, I., Martínez-Navarrete, G., Menéndez, M., López-Méndez, T., Soto-Sánchez, C., Zárate, J., Puras, G., Fernández, E., & Pedraz, J. L. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.12.018 · Cited by 50
The Off-Targets of Clustered Regularly Interspaced Short Palindromic Repeats Gene Editing
Vicente, M. M., Chaves‐Ferreira, M., Jorge, J. M. P., Proença, J. T., & Barreto, V. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.718466 · Cited by 42
The Interplay between Viruses and Host DNA Sensors
Huérfano, S., Šroller, V., Bruštíková, K., Horníková, L., & Forstová, J. (2022) · Viruses · doi:10.3390/v14040666 · Cited by 42
Massively targeted evaluation of therapeutic CRISPR off-targets in cells
Pan, X., Qu, K., Yuan, H., Xiang, X., Anthon, C., Pashkova, L., Liang, X., Han, P., Corsi, G. I., Xu, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31543-6 · Cited by 42 · cited 1×
“Although gene-editing techniques are precise and efficient, they are still known to have off-target effects.(31,32) Newer technologies are being developed to circumvent this issue, but none of them guarantee Figure 1 Distribution of (A) Naturally occurring AAVs (blue) and engineered AAVs (Orange) used in 53 clinical t…”
Herzog, R. W., Cooper, M., Perrin, G. Q., Biswas, M., Martino, A. T., Morel, L., Terhorst, C., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.012 · Cited by 39
Dufour, V. L., Cideciyan, A. V., Ye, G.-J., Song, C., Timmers, A., Habecker, P. L., Pan, W., Weinstein, N. M., Swider, M., Durham, A. C., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.297 · Cited by 39
Simon, C.-J., Sahel, J.-A., Duebel, J., Herlitze, S., & Dalkara, D. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.12.117 · Cited by 38
Self-citationSalman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Holmgaard, A. B., Askou, A. L., Jensen, E. G., Alsing, S., Bak, R. O., Mikkelsen, J. G., & Corydon, T. J. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.032 · Cited by 36
Generative AAV capsid diversification by latent interpolation
Sinai, S., Jain, N., Church, G. M., & Kelsic, E. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.16.440236 · Cited by 33
Selot, R., Hareendran, S., & Jayandharan, G. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140327141710 · Cited by 31
Han, I. C., Burnight, E. R., Ulferts, M. J., Worthington, K. S., Russell, S. R., Sohn, E. H., Mullins, R. F., Stone, E. M., Tucker, B. A., & Wiley, L. A. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.159 · Cited by 30
Madrigal, J. L., Shams, S., Stilhano, R. S., & Silva, E. A. (2018) · Biomaterials Science · doi:10.1039/c8bm01218k · Cited by 29
Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene Therapy
Boye, S. L., Choudhury, S., Crosson, S., Di Pasquale, G., Afione, S., Mellen, R., Makal, V., Calabro, K. R., Fajardo, D., Peterson, J., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.002 · Cited by 29 · cited 1×
“Moreover, AAV has limited reach outside of the bleb due to restricted lateral spread.(92,93) While IVTs permit AAV to reach a larger area of the tissue, they nevertheless require vitrectomies and result in poor transduction of the inner and outer retina due to physical barriers such as the ILM.”
BackgroundSong, C., Dufour, V. L., Cideciyan, A. V., Ye, G.-J., Swider, M., Newmark, J. A., Timmers, A. M., Robinson, P. M., Knop, D. R., Chulay, J. D., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.337 · Cited by 28 · cited 1×
“As such, the variant AAV2tYF (three tyrosine to phenylalanine substitutions, Y444F, Y500F, Y730F) has shown improved transduction profiles in canine animal models by evading degradation through the proteasome complex.(97,98) AAV2tYF is currently in use in four clinical trials (Table 1), both through SR and IVT injecti…”
BackgroundSafety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27
Spatial Organization and Dynamics of the Extracellular Space in the Mouse Retina
Kuo, S. P., Chiang, P.-P., Nippert, A. R., & Newman, E. A. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.1717-20.2020 · Cited by 24
New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies
Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · The CRISPR Journal · doi:10.1089/crispr.2021.0141 · Cited by 23
Self-citationBase and Prime Editing in the Retina—From Preclinical Research toward Human Clinical Trials
Yee, T., & Wert, K. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012375 · Cited by 22
Li, Y., Li, J., Liu, Y., Shi, Z., Liu, H., Wei, Y., & Yang, L. (2019) · Gene Therapy · doi:10.1038/s41434-019-0081-8 · Cited by 21
Quantitative single-cell transcriptome-based ranking of engineered AAVs in human retinal explants
Xi, Z., Öztürk, B. E., Johnson, M. E., Turunç, S., Stauffer, W. R., & Byrne, L. C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.014 · Cited by 21
Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20
Assessment of AAV Dual Vector Safety in the Abca4−/− Mouse Model of Stargardt Disease
McClements, M. E., Barnard, A. R., Charbel Issa, P., & MacLaren, R. E. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.20 · Cited by 18
Inflammation and Immunology of the Vitreoretinal Compartment
Böhm, M. R. R., Oellers, P. R., & Thanos, S. (2011) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152811796117717 · Cited by 16
Aalbers, C. J., Broekstra, N., van Geldorp, M., Kramer, E., Ramiro, S., Tak, P. P., Vervoordeldonk, M. J., & Finn, J. D. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.036 · Cited by 16
Ross, M., Obolensky, A., Averbukh, E., Desrosiers, M., Ezra-Elia, R., Honig, H., Yamin, E., Rosov, A., Dvir, H., Gootwine, E., et al. (2022) · Gene Therapy · doi:10.1038/s41434-021-00306-1 · Cited by 13
Self-citationACIDES: on-line monitoring of forward genetic screens for protein engineering
Nemoto, T., Ocari, T., Planul, A., Tekinsoy, M., Zin, E. A., Dalkara, D., & Ferrari, U. (2023) · Nature Communications · doi:10.1038/s41467-023-43967-9 · Cited by 7
Self-citationUncursing winner’s curse: on-line monitoring of directed evolution convergencePreprint
Nemoto, T., Ocari, T., Planul, A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.03.522172 · Cited by 2
Cited by
Nucleic acid-based drugs for patients with solid tumours
Huayamares, S. G., Loughrey, D., Kim, H., Dahlman, J. E., & Sorscher, E. J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00883-1 · Cited by 61
Agrahari, V., Choonara, Y. E., Mosharraf, M., Patel, S. K., & Zhang, F. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03798-9 · Cited by 61
Combined AAV-mediated specific Gjb2 expression restores hearing in DFNB1 mouse models
Sun, Q., Tan, F., Zhang, L., Lu, Y., Hao, W., Li, N., Jiang, L., Zhou, Y., Chen, T., Ling, L., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.029 · Cited by 43
An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
Luo, S., Jiang, H., Li, Q., Qin, Y., Yang, S., Li, J., Xu, L., Gou, Y., Zhang, Y., Liu, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48221-4 · Cited by 39
“A goodcapsid variant possesses immensecommercialvalue and holds promising prospects for application 13,51 .”
Breaking genetic shackles: The advance of base editing in genetic disorder treatment
Xu, F., Zheng, C., Xu, W., Zhang, S., Liu, S., Chen, X., & Yao, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364135 · Cited by 34
Metadata
- Authors
- Ail, D., Malki, H., Zin, E. A., & Dalkara, D.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Ail, Divya
- Malki, Hugo
- Zin, Emilia A
- Dalkara, Deniz
- Venue
- The Application of Clinical Genetics
- Publisher
- Informa UK Limited
- Published
- 2023-05
- Volume
- Volume 16
- Pages
- 111-130
- ISSN
- 1178-704X (ISSN-L)
- PMC
- PMC10239239
- OpenAlex
- W4379377001
- Cited by
- 40
- References
- 139
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 17 · 2023: 3
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The Application of Clinical Genetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, retinal gene therapy, adeno-associated virus vectors, retinal transduction, outer retina, retinal disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.